Structural and refractive outcomes of intravitreal ranibizumab followed by laser photocoagulation for type 1 retinopathy of prematurity

[1]  J. Demer,et al.  Real-world visual outcomes of laser and anti-VEGF treatments for retinopathy of prematurity , 2021, American Journal of Ophthalmology.

[2]  R. Azad,et al.  Outcomes of early versus deferred laser after intravitreal ranibizumab in aggressive posterior retinopathy of prematurity , 2021, Indian journal of ophthalmology.

[3]  A. Berrocal,et al.  Retinopathy of Prematurity: Advances in the Screening and Treatment of Retinopathy of Prematurity Using a Single Center Approach. , 2021, American journal of ophthalmology.

[4]  D. Wallace,et al.  International Classification of Retinopathy of Prematurity, Third Edition. , 2021, Ophthalmology.

[5]  Achim Zeileis,et al.  Various versatile variances : An object-oriented implementation of clustered covariances in R Working , 2017 .

[6]  Wei-Chi Wu,et al.  RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY. , 2019, Retina.

[7]  N. Marlow,et al.  Ranibizumab versus laser therapy for the treatment of very low birthweight infants with retinopathy of prematurity (RAINBOW): an open-label randomised controlled trial , 2019, The Lancet.

[8]  Samir N. Patel,et al.  Evidence to date: ranibizumab and its potential in the treatment of retinopathy of prematurity , 2019, Eye and brain.

[9]  S. Dai,et al.  Persistent Avascular Retina in Infants With a History of Type 2 Retinopathy of Prematurity: To Treat or Not to Treat? , 2019, Journal of pediatric ophthalmology and strabismus.

[10]  H. Hashemi,et al.  Global and regional prevalence of strabismus: a comprehensive systematic review and meta-analysis , 2019, Strabismus.

[11]  M. Blair,et al.  Refractive outcomes comparing primary laser to primary bevacizumab with delayed laser for type 1 ROP. , 2018, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[12]  Lois E. H. Smith,et al.  A Dosing Study of Bevacizumab for Retinopathy of Prematurity: Late Recurrences and Additional Treatments. , 2018, Ophthalmology.

[13]  Min Kim,et al.  Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes , 2018, Korean journal of ophthalmology : KJO.

[14]  Lois E. H. Smith,et al.  Comparing Alternative Ranibizumab Dosages for Safety and Efficacy in Retinopathy of Prematurity: A Randomized Clinical Trial , 2018, JAMA pediatrics.

[15]  J. García-González,et al.  Very Late Reactivation of Retinopathy of Prematurity After Monotherapy With Intravitreal Bevacizumab. , 2016, Ophthalmic surgery, lasers & imaging retina.

[16]  D. Coats,et al.  Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity. , 2015, Investigative ophthalmology & visual science.

[17]  A. Chuang,et al.  Refractive outcomes following bevacizumab monotherapy compared with conventional laser treatment: a randomized clinical trial. , 2014, JAMA ophthalmology.

[18]  Y. Hwang,et al.  Refractive errors after the use of bevacizumab for the treatment of retinopathy of prematurity: 2-year outcomes , 2014, Eye.

[19]  Neil Marlow,et al.  Preterm birth–associated neurodevelopmental impairment estimates at regional and global levels for 2010 , 2013, Pediatric Research.

[20]  David L. Rogers,et al.  Prevalence and course of strabismus through age 6 years in participants of the Early Treatment for Retinopathy of Prematurity randomized trial. , 2011, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[21]  Alice Z Chuang,et al.  Efficacy of intravitreal bevacizumab for stage 3+ retinopathy of prematurity. , 2011, The New England journal of medicine.

[22]  K. Ghasemi Falavarjani,et al.  Intravitreal bevacizumab in combination with laser therapy for the treatment of severe retinopathy of prematurity (ROP) associated with vitreous or retinal hemorrhage , 2010, Graefe's Archive for Clinical and Experimental Ophthalmology.

[23]  D. Coats,et al.  Prevalence and course of strabismus in the first year of life for infants with prethreshold retinopathy of prematurity: findings from the Early Treatment for Retinopathy of Prematurity study. , 2010, Archives of ophthalmology.

[24]  E. Palmer.  Results of U.S. randomized clinical trial of cryotherapy for ROP (CRYO-ROP) , 1990, Documenta Ophthalmologica.

[25]  R. Hardy,et al.  Prevalence of myopia at 9 months in infants with high-risk prethreshold retinopathy of prematurity. , 2005, Ophthalmology.

[26]  Y. Yu,et al.  RETINAL DETACHMENT OF REGRESSED RETINOPATHY OF PREMATURITY IN CHILDREN AGED 2 TO 15 YEARS , 2004, Retina.

[27]  U. Kellner,et al.  [Late Retinal Complications in Former Preterm Infants with Regressed ROP]. , 2004, Klinische Monatsblatter fur Augenheilkunde.

[28]  William V Good,et al.  Final results of the Early Treatment for Retinopathy of Prematurity (ETROP) randomized trial. , 2004, Transactions of the American Ophthalmological Society.

[29]  E. Palmer,et al.  Strabismus in premature infants in the first year of life. Cryotherapy for Retinopathy of Prematurity Cooperative Group. , 1998, Archives of ophthalmology.

[30]  Multicenter trial of cryotherapy for retinopathy of prematurity. One-year outcome--structure and function. Cryotherapy for Retinopathy of Prematurity Cooperative Group. , 1990, Archives of ophthalmology.